Yahoo
NasdaqCM - Delayed Quote USD

Precipio, Inc. (PRPO)

18.10 -1.25 (-6.46%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for PRPO
  • Previous Close 19.35
  • Open 19.83
  • Bid 15.52 x 100
  • Ask 21.07 x 100
  • Day's Range 17.99 - 19.83
  • 52 Week Range 17.99 - 33.63
  • Volume 25,900
  • Avg. Volume 105,582
  • Market Cap (intraday) 32.402M
  • Beta (5Y Monthly) 1.30
  • PE Ratio (TTM) --
  • EPS (TTM) -0.64
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est --
  • Motley Fool Rating Bearish

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.

www.precipiodx.com

61

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PRPO
21.24%
S&P 500 (^GSPC)
10.73%

1-Year Return

PRPO
11.58%
S&P 500 (^GSPC)
11.11%

3-Year Return

PRPO
128.39%
S&P 500 (^GSPC)
81.91%

5-Year Return

PRPO
61.65%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY23
Revenue 4.52M
Earnings -1.46M
Profit Margin -32.20%

Q4

FY22

Q1

FY23

Q2

FY23

Q3

FY23

-2M
0
2M
4M
-100.0%
-80.0%
-60.0%
-40.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -4.47%

  • Return on Assets (ttm)

    -4.81%

  • Return on Equity (ttm)

    -8.98%

  • Revenue (ttm)

    27.2M

  • Net Income Avi to Common (ttm)

    -1.22M

  • Diluted EPS (ttm)

    -0.64

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.08M

  • Total Debt/Equity (mrq)

    24.31%

  • Levered Free Cash Flow (ttm)

    1.35M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: